Gu L - Search Results

1

The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA.

Gu L, Lingeman R, Yakushijin F, Sun E, Cui Q, Chao J, Hu W, Li H, Hickey RJ, Stark JM, Yuan YC, Chen Y, Vonderfecht SL, Synold TW, Shi Y, Reckamp KL, Horne D, Malkas LH. Gu L, et al. Clin Cancer Res. 2018 Dec 1;24(23):6053-6065. doi: 10.1158/1078-0432.CCR-18-0592. Epub 2018 Jul 2. Clin Cancer Res. 2018. PMID: 29967249 Free PMC article.

2

A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging.

Gu L, Tsark WM, Brown DA, Blanchard S, Synold TW, Kane SE. Gu L, et al. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5394-9. doi: 10.1073/pnas.0807343106. Epub 2009 Mar 12. Proc Natl Acad Sci U S A. 2009. PMID: 19282474 Free PMC article.

3

Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines.

Gu L, Lau SK, Loera S, Somlo G, Kane SE. Gu L, et al. Clin Cancer Res. 2009 Dec 1;15(23):7196-206. doi: 10.1158/1078-0432.CCR-09-0585. Epub 2009 Nov 17. Clin Cancer Res. 2009. PMID: 19920112 Free PMC article.

4

Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice.

Gu L, Chen J, Synold TW, Forman BM, Kane SE. Gu L, et al. J Pharmacol Exp Ther. 2013 Jun;345(3):438-45. doi: 10.1124/jpet.113.203562. Epub 2013 Mar 26. J Pharmacol Exp Ther. 2013. PMID: 23532932 Free PMC article.

5

A PCNA-derived cell permeable peptide selectively inhibits neuroblastoma cell growth.

Gu L, Smith S, Li C, Hickey RJ, Stark JM, Fields GB, Lang WH, Sandoval JA, Malkas LH. Gu L, et al. PLoS One. 2014 Apr 11;9(4):e94773. doi: 10.1371/journal.pone.0094773. eCollection 2014. PLoS One. 2014. PMID: 24728180 Free PMC article.

6

A Peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer.

Smith SJ, Gu L, Phipps EA, Dobrolecki LE, Mabrey KS, Gulley P, Dillehay KL, Dong Z, Fields GB, Chen YR, Ann D, Hickey RJ, Malkas LH. Smith SJ, et al. Among authors: gu l. Mol Pharmacol. 2015 Feb;87(2):263-76. doi: 10.1124/mol.114.093211. Epub 2014 Dec 5. Mol Pharmacol. 2015. PMID: 25480843 Free PMC article.

7

The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells.

Gu L, Chu P, Lingeman R, McDaniel H, Kechichian S, Hickey RJ, Liu Z, Yuan YC, Sandoval JA, Fields GB, Malkas LH. Gu L, et al. EBioMedicine. 2015 Nov 10;2(12):1923-31. doi: 10.1016/j.ebiom.2015.11.016. eCollection 2015 Dec. EBioMedicine. 2015. PMID: 26844271 Free PMC article.

8

Novel Peptide Therapeutic Approaches for Cancer Treatment.

Li CM, Haratipour P, Lingeman RG, Perry JJP, Gu L, Hickey RJ, Malkas LH. Li CM, et al. Among authors: gu l. Cells. 2021 Oct 27;10(11):2908. doi: 10.3390/cells10112908. Cells. 2021. PMID: 34831131 Free PMC article. Review.

9

Arginine shortage induces replication stress and confers genotoxic resistance by inhibiting histone H4 translation and promoting PCNA ubiquitination.

Wang YC, Kelso AA, Karamafrooz A, Chen YH, Chen WK, Cheng CT, Qi Y, Gu L, Malkas L, Taglialatela A, Kung HJ, Moldovan GL, Ciccia A, Stark JM, Ann DK. Wang YC, et al. Among authors: gu l. Cell Rep. 2023 Apr 25;42(4):112296. doi: 10.1016/j.celrep.2023.112296. Epub 2023 Mar 23. Cell Rep. 2023. PMID: 36961817 Free PMC article.

10

Therapeutic Targeting of DNA Replication Stress in Cancer.

Gu L, Hickey RJ, Malkas LH. Gu L, et al. Genes (Basel). 2023 Jun 26;14(7):1346. doi: 10.3390/genes14071346. Genes (Basel). 2023. PMID: 37510250 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,927 results

Search Page

Filters